New hope for bile duct cancer: targeted combo trial launches

NCT ID NCT07036380

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire de Besancon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, MP0317, combined with standard chemotherapy and immunotherapy for people with advanced bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps keep the cancer from growing for at least 12 months. About 75 adults will take part, and researchers will also study how the immune system responds to the treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BILIARY TRACT CARCINOMA

Contacts and locations

Locations

CHU de Besançon
RECRUITING

Besançon, France
CHU de Grenoble
RECRUITING

Grenoble, France
CHU de Montpellier
RECRUITING

Montpellier, France
CHU de Tours
RECRUITING

Tours, France
Centre Eugène Marquis
RECRUITING

Rennes, France
Centre Léon Bérard
RECRUITING

Lyon, France
Centre georges-François Leclerc
RECRUITING

Dijon, France
Hôpital Beaujon
RECRUITING

Paris, France
Hôpital La Pitié-Salpétrière
RECRUITING

Paris, France
Institut Curie
NOT_YET_RECRUITING

Paris, France
Institut Gustave Roussy
NOT_YET_RECRUITING

Villejuif, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.